Paris, France

Micheline Charpentiermorize

This inventor holds 1 USPTO granted patent. Top assignee: Laboratoires Lucien. Active years: 1992.


% Patents Active = 100.0

Average Co-Inventor Count = 4.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 1992

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Micheline Charpentiermorize: Innovator in Chemical Derivatives

Introduction

Micheline Charpentiermorize is a notable inventor based in Paris, France. She has made significant contributions to the field of chemistry, particularly in the development of novel chemical compounds. Her work has led to the creation of a patent that showcases her innovative spirit and expertise.

Latest Patents

Micheline holds a patent for "Derivatives of 4-amino-1-trifluoromethyltetralines their preparation and use." This patent highlights her ability to synthesize complex chemical derivatives, which can have various applications in the pharmaceutical industry. She has 1 patent to her name, reflecting her dedication to advancing chemical research.

Career Highlights

Throughout her career, Micheline has been associated with Laboratoires Lucien, where she has contributed to various research projects. Her work has not only advanced her career but has also positively impacted the scientific community. Micheline's innovative approach to problem-solving has earned her recognition among her peers.

Collaborations

Micheline has collaborated with esteemed colleagues, including Daniele Bonnet Delpon and Jean-Pierre Begue. These collaborations have fostered a creative environment that encourages the exchange of ideas and the pursuit of groundbreaking research.

Conclusion

Micheline Charpentiermorize is a remarkable inventor whose work in chemical derivatives has made a significant impact in her field. Her dedication to innovation and collaboration continues to inspire others in the scientific community.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…